Featured

Fortis Healthcare launches Institute of Genomic Medicine in Precision Medicine

Fortis Healthcare has launched Institute of Genomic Medicines’, a pioneering center dedicated to harnessing the power of genomic science to transform patient care across India. Backed by Fortis’ advanced clinical ecosystem and Agilus Diagnostics’ extensive national footprint, the institute will bring together a multi-disciplinary team of medical experts including Molecular Hematology, Oncology, Neurology, Pediatrics, Pathology, Genomic scientists alongwith bioinformaticians and AI (artificial intelligence) engineers.

Genomics is transforming the future of modern medicine and treatment modalities across specialties – Oncology, Cardiology, Neurology. Onco-genomics will help clinicians decode the genetic drivers of cancer, enabling targeted therapies that are more effective and less toxic than traditional one-size-fits-all treatments. Cardio-genomics will empower the early detection of inherited cardiac conditions, crucial for families with a history of sudden cardiac arrest, unexplained heart failure, or congenital heart disease. Meanwhile, Neuro-genomics will offer new hope for patients with complex neurological disorders, using gene-based insights to improve diagnosis and personalize interventions for conditions like epilepsy, Parkinson’s and rare neurodevelopmental syndromes. The power of Genomics, has already delivered life-changing outcomes: a leukemia patient, initially headed for a transplant, received a new course of treatment following a precise genetic diagnosis; a woman with a silent hereditary cancer risk underwent genomic screening, leading to early detection and preventive care for three family members; and a lung cancer patient with a previously undetected MET-ST7 fusion (a genetic alteration)—identified solely through Fortis’ Next-Generation Sequencing (NGS)—is now thriving on targeted therapy.

Mr Anil Vinayak, Group Chief Operating Officer, Fortis Healthcare said, “The launch of the Fortis Institute of Genomic Medicine is a strategic step forward in our vision to be at the forefront of transformative healthcare. By integrating genomics into our core offerings, we are enhancing our ability to deliver personalized, data-driven care while strengthening our clinical leadership in clinical innovation.”

Dr. Ritu Garg, Chief Innovation and Growth Officer, Fortis Healthcare said, “The launch of the Fortis Institute of Genomic Medicine is a strategic leap in our pursuit of future-ready healthcare. At Fortis, we recognize that the future of medicine lies in precision and personalization. This institute reflects our vision to integrate cutting-edge science with clinical excellence, enabling us to drive better patient outcomes and redefine standards of care. As leaders in the healthcare ecosystem, we are committed to fostering innovation that is scalable, sustainable, and deeply impactful.”

Yash Rawat, Facility Director, Fortis Memorial Research Institute, Gurugram said, “Genomic testing is revolutionizing the way we approach health and chronic ailments. It will be crucial in curbing non-communicable diseases by enhancing early disease detection, treatment precision, and risk assessment. Whether it’s a child with unexplained anemia, a woman with a family history of breast cancer, or a lung cancer patient needing targeted therapy, genomics changes the game by personalizing the treatment approach. By analyzing one’s DNA, one can uncover vital information about one’s inherited risk factors, how one metabolizes medications, and one’s susceptibility to certain diseases.”

Medlarge

Recent Posts

AIIMS Doctor perform congenital lung malformation rare surgery on 4-month child

Doctors at AIIMS Delhi have successfully performed a rare and technically demanding lung-preserving surgery on…

1 week ago

22-year-old woman undergoes for decade long facial tumour through Scarless Surgery

Sharda Hospital successfully performed a rare scarless surgery to remove a massive benign facial tumor…

3 weeks ago

29-year-old woman undergoes breast reconstruction for childhood burn deformity

A 29-year-old woman with a severe post-burn deformity of the left chest and breast, resulting…

3 weeks ago

Zydus signs MoU with Apollo Hospitals for multi-cancer early detection test

Zydus Lifesciences with Guardant Health, having an agreement to make the Shield™ Multi-Cancer Detection (MCD)…

3 weeks ago

Why India needs uniform strategy for equitable access to Cancer treatment, experts explain

In the backdrop of observation that India may emerge as the Cancer Capital of the…

3 weeks ago

Centre bans sale of Cough syrups without valid prescription

The Centre has amended the Drugs rule, omitting the word “Syrup” from Schedule K, the…

1 month ago